Compare Mesoblast Limited (MESO) vs Vanguard High Dividend Yield ETF (VYM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Vanguard High Dividend Yield ETF — how do they compare? Mesoblast Limited trades at $16.69 (market cap $2.18B), while Vanguard High Dividend Yield ETF trades at $160.14. The key difference: Vanguard High Dividend Yield ETF is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals.
| MESO | VYM | |
|---|---|---|
Market Cap | $2.18B | — |
Sector | Technology | — |
52-Week High | $20.96 | $161.17 |
52-Week Low | $12.88 | $132.90 |
Enterprise Value | $2.18B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.83, down 2.83% today, with a bullish technical signal supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a -144% net income margin. Recent positive developments include Phase 3 trial milestones and FDA BLA filing progress for heart failure treatment.
Investment outlook balances promising commercial traction against significant financial losses. Analyst consensus leans bullish (45% buy ratings) but high P/S ratio of 30.5x and persistent cash burn present substantial risk. Key catalysts include regulatory approvals and path to profitability.
Vanguard High Dividend Yield ETF (VYM) trades at $160.49, showing modest daily gains of 0.21% with bullish technical signals from moving averages. The ETF manages $94.6 billion in assets and generates significant income through dividend-paying large-cap stocks. Recent institutional buying activity and positive media coverage highlight its appeal for income-focused investors, particularly retirees seeking tax-efficient monthly income streams.
VYM offers broad diversification across 618 holdings with an ultra-low 0.04% expense ratio, positioning it as a core income vehicle. The primary opportunity lies in consistent dividend income generation, while risks include interest rate sensitivity and potential underperformance during growth-oriented market cycles compared to broader indices.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Vanguard High Dividend Yield ETF
The advisor employs an indexing investment approach designed to track the performance of the index, which consists of common stocks of companies that pay dividends that generally are higher than average. The advisor attempts to replicate the target index by investing all, or substantially all, of the fund's assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VYM →
